356 related articles for article (PubMed ID: 32721116)
1. Comparison of prostate-specific membrane antigen ligands in clinical translation research for diagnosis of prostate cancer.
Sengupta S; Asha Krishnan M; Chattopadhyay S; Chelvam V
Cancer Rep (Hoboken); 2019 Aug; 2(4):e1169. PubMed ID: 32721116
[TBL] [Abstract][Full Text] [Related]
2. Photosensitizer-based multimodal PSMA-targeting ligands for intraoperative detection of prostate cancer.
Derks YHW; Rijpkema M; Amatdjais-Groenen HIV; Kip A; Franssen GM; Sedelaar JPM; Somford DM; Simons M; Laverman P; Gotthardt M; Löwik DWPM; Lütje S; Heskamp S
Theranostics; 2021; 11(4):1527-1541. PubMed ID: 33408764
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges.
Rowe SP; Gorin MA; Allaf ME; Pienta KJ; Tran PT; Pomper MG; Ross AE; Cho SY
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):223-30. PubMed ID: 27136743
[TBL] [Abstract][Full Text] [Related]
5. [
Bauman G; Martin P; Thiessen JD; Taylor R; Moussa M; Gaed M; Rachinsky I; Kassam Z; Chin J; Pautler S; Lee TY; Valliant JF; Ward A
Eur Urol Focus; 2018 Sep; 4(5):702-706. PubMed ID: 28753797
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and Evaluation of
Zhao R; Ploessl K; Zha Z; Choi S; Alexoff D; Zhu L; Kung HF
Mol Pharm; 2020 Dec; 17(12):4589-4602. PubMed ID: 33108189
[TBL] [Abstract][Full Text] [Related]
7. A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer.
Chatalic KL; Veldhoven-Zweistra J; Bolkestein M; Hoeben S; Koning GA; Boerman OC; de Jong M; van Weerden WM
J Nucl Med; 2015 Jul; 56(7):1094-9. PubMed ID: 25977460
[TBL] [Abstract][Full Text] [Related]
8. PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status.
Lütje S; Heskamp S; Cornelissen AS; Poeppel TD; van den Broek SA; Rosenbaum-Krumme S; Bockisch A; Gotthardt M; Rijpkema M; Boerman OC
Theranostics; 2015; 5(12):1388-401. PubMed ID: 26681984
[TBL] [Abstract][Full Text] [Related]
9. 99mTc-labeled small-molecule inhibitors of prostate-specific membrane antigen for molecular imaging of prostate cancer.
Hillier SM; Maresca KP; Lu G; Merkin RD; Marquis JC; Zimmerman CN; Eckelman WC; Joyal JL; Babich JW
J Nucl Med; 2013 Aug; 54(8):1369-76. PubMed ID: 23733925
[TBL] [Abstract][Full Text] [Related]
10. Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer.
Kratochwil C; Afshar-Oromieh A; Kopka K; Haberkorn U; Giesel FL
Semin Nucl Med; 2016 Sep; 46(5):405-18. PubMed ID: 27553466
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific membrane antigen targeted imaging and therapy of prostate cancer using a PSMA inhibitor as a homing ligand.
Kularatne SA; Wang K; Santhapuram HK; Low PS
Mol Pharm; 2009; 6(3):780-9. PubMed ID: 19361233
[TBL] [Abstract][Full Text] [Related]
12. A cell-impermeable luminogenic probe for near-infrared imaging of prostate-specific membrane antigen in prostate cancer microenvironments.
Yang X; Nao SC; Lin C; Kong L; Wang J; Ko CN; Liu J; Ma DL; Leung CH; Wang W
Eur J Med Chem; 2023 Nov; 259():115659. PubMed ID: 37499288
[TBL] [Abstract][Full Text] [Related]
13. PSMA-targeted dendrimers: a patent evaluation (WO2012078534).
Akhtar NH; Osborne JR; Fareedy SB; Tagawa ST
Expert Opin Ther Pat; 2013 May; 23(5):665-8. PubMed ID: 23581819
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific membrane antigen-guided salvage lymph node dissection in recurrent prostate cancer: a novel technology to detect lymph node metastases.
Maurer T; Gschwend JE; Eiber M
Curr Opin Urol; 2018 Mar; 28(2):191-196. PubMed ID: 29028767
[TBL] [Abstract][Full Text] [Related]
15. Design and Characterization of Squaramic Acid-Based Prostate-Specific Membrane Antigen Inhibitors for Prostate Cancer.
Wang X; Chen Y; Xiong Y; Zhang L; Wang B; Liu Y; Cui M
J Med Chem; 2023 May; 66(10):6889-6904. PubMed ID: 37161996
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and Biologic Evaluation of Novel 18F-Labeled Probes Targeting Prostate-Specific Membrane Antigen for PET of Prostate Cancer.
Harada N; Kimura H; Onoe S; Watanabe H; Matsuoka D; Arimitsu K; Ono M; Saji H
J Nucl Med; 2016 Dec; 57(12):1978-1984. PubMed ID: 27417647
[TBL] [Abstract][Full Text] [Related]
17. Radiolabeled mAbs as Molecular Imaging and/or Therapy Agents Targeting PSMA.
Psimadas D; Valotassiou V; Alexiou S; Tsougos I; Georgoulias P
Cancer Invest; 2018 Feb; 36(2):118-128. PubMed ID: 29393702
[TBL] [Abstract][Full Text] [Related]
18. PSMA PET and Radionuclide Therapy in Prostate Cancer.
Bouchelouche K; Turkbey B; Choyke PL
Semin Nucl Med; 2016 Nov; 46(6):522-535. PubMed ID: 27825432
[TBL] [Abstract][Full Text] [Related]
19. Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate.
Lv Q; Yang J; Zhang R; Yang Z; Yang Z; Wang Y; Xu Y; He Z
Mol Pharm; 2018 May; 15(5):1842-1852. PubMed ID: 29608845
[TBL] [Abstract][Full Text] [Related]
20. Assessment of PSMA targeting ligands bearing novel chelates with application to theranostics: Stability and complexation kinetics of
Kelly JM; Amor-Coarasa A; Nikolopoulou A; Kim D; Williams C; Vallabhajosula S; Babich JW
Nucl Med Biol; 2017 Dec; 55():38-46. PubMed ID: 29055836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]